We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Perifollicular Doppler in Natural Cycle In Vitro Fertilization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01668212
Recruitment Status : Completed
First Posted : August 20, 2012
Last Update Posted : June 24, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:

Perifollicular Doppler could reflect the quality of the follicle's vascularization and, consequently, the one of the oocyte that ensues from it. Perifollicuar Doppler is the analysis, in ultrasound, of the blood flow in vessels surrounding the follicle.

The goal of this study is to evaluate if there is a link, in natural cycle In Vitro Fertilization, between the quality of the vascularization and the one of the oocyte, the embryo and the pregnancy.

Condition or disease Intervention/treatment
Infertility Procedure: Doppler ultrasound

Study Design

Study Type : Observational
Actual Enrollment : 160 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Perifollicular Doppler in Natural Cycle In Vitro Fertilization
Study Start Date : March 2012
Primary Completion Date : May 2013
Groups and Cohorts

Group/Cohort Intervention/treatment
natural In Vitro Fertilization cycle
Patient doing following natural In Vitro fertilization cycle
Procedure: Doppler ultrasound
Doppler Ultrasound

Outcome Measures

Primary Outcome Measures :
  1. Quality perifollicular doppler and quality of the oocyte [ Time Frame: 2 weeks ]
    The measurements are done twice; on days of induction and oocyte retrieval. During the blood sample collection on the day of the induction, there is also a measurement of progesterone, estradiol and luteinizing hormone (LH).

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 38 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Women following In Vitro Fertilization cycle

Inclusion Criteria:

  • Patient with a natural In Vitro Fertilization cycle.
  • Patient under 38 years old
  • Body mass indice under 35
  • Ovulatory cycles between 20-35 days

Exclusion Criteria:

  • Patient with a stimulation In Vitro Fertilization cycle
  • Patient with a naturalIn Vitro Fertilization cycle with egg donor
  • Patient with a natural In Vitro Fertilization cycle with freezing embryo
  • Smoking patient
  • Diabetic patient
  • Patient with treatment of antihypertensive drug, anticoagulant, antiplatelet, vasodilator
  • Body mass indice over 35
  • Patient over 38 years old
  • Patient without ovulation or cycle over 35 days
  • Percutaneous Epididymal Sperm Aspiration (PESA), Testicular Sperm Extraction (TESE) or micro TESE
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01668212

Canada, Quebec
Ovo Fertilité
Montréal, Quebec, Canada, H4P 2S4
Sponsors and Collaborators
Principal Investigator: Delphine Delrieu, MD Clinique ovo
More Information

Responsible Party: OVO R & D
ClinicalTrials.gov Identifier: NCT01668212     History of Changes
Other Study ID Numbers: OVO-11-01
First Posted: August 20, 2012    Key Record Dates
Last Update Posted: June 24, 2013
Last Verified: June 2013

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female